An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2015
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors UCB
- 20 Apr 2015 Post-hoc analysis of pooled data presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), according to a UCB media release.
- 16 Oct 2009 Additional locations (USA, Canada) identified as reported by ClinicalTrials.gov.
- 09 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.